Page 1 | Search Results | Blood | American Society of Hematology

1-13 of 13

Sort by

Sort Order Select

Journal Articles

Efficacy and Safety of Daratumumab Monotherapy in Newly Diagnosed Patients with Stage 3B Light Chain Amyloidosis: A Phase 2 Study By the European Myeloma Network

Efstathios Kastritis, Monique C Minnema, Meletios-Athanasios Dimopoulos, Giampaolo Merlini, Foteini Theodorakakou, Despina Fotiou, Antoine Huart, Karim Belhadj Merzoug, Stavros Golfinopoulos, Nasia Antoniou, Giorgos Psarros, Pieter Sonneveld, Giovanni O. Palladini

Blood (2024) 144 (Supplement 1): 1979.

https://doi.org/10.1182/blood-2024-202932

Published: 2024

Journal Articles

Efficacy and Safety of Isatuximab, Pomalidomide and Dexamethasone in Relapsed AL Amyloidosis: Interim Results of the Isamyp Phase 2 Joint Study from the IFM and ALLG

Blood (2024) 144 (Supplement 1): 892.

https://doi.org/10.1182/blood-2024-204700

Published: 2024

Journal Articles

Subcutaneous Daratumumab (DARA) + Bortezomib, Cyclophosphamide, and Dexamethasone (VCd) in Patients with Newly Diagnosed Light Chain (AL) Amyloidosis: Overall Survival and Final Major Organ Deterioration Progression-Free Survival Results from the Phase 3 Andromeda Study

Blood (2024) 144 (Supplement 1): 891.

https://doi.org/10.1182/blood-2024-205077

Published: 2024

Journal Articles

Teclistamab in relapsed or refractory AL amyloidosis: a multinational retrospective case series

Blood (2024) 143 (8): 734–737.

https://doi.org/10.1182/blood.2023022937

Published: 2024

Journal Articles

Teclistamab in Relapsed Refractory Multiple Myeloma Patients on Dialysis: A French Experience

Florence Lachenal, Pierre Lebreton, Sylvie Bouillie, Gian Matteo Pica, Hassina Aftisse, Laurent Pascal, Lydia Montes, Margaret Macro, Marguerite Vignon, Stephanie Harel, Mariana Fernandez, Chanaz Louni, Antoine Huart, Aurore Perrot

Blood (2023) 142 (Supplement 1): 4739.

https://doi.org/10.1182/blood-2023-180660

Published: 2023

Journal Articles

Efficacy and Safety of Daratumumab Monotherapy in Newly Diagnosed Patients with Stage 3B Light-Chain Amyloidosis: A Phase 2 Study By the European Myeloma Network

Efstathios Kastritis, Monique C Minnema, Meletios A. Dimopoulos, Giampaolo Merlini, Foteini Theodorakakou, Despina Fotiou, Antoine Huart, Karim Belhadj Merzoug, Elena Papachristou, Kyriaki Manousou, Pieter Sonneveld, Giovanni Palladini

Blood (2023) 142 (Supplement 1): 539.

https://doi.org/10.1182/blood-2023-185811

Published: 2023

Journal Articles

Birtamimab: a new amyloidosis treatment?

Antoine Huart

Blood (2023) 142 (14): 1178–1180.

https://doi.org/10.1182/blood.2023021311

Published: 2023

Journal Articles

A Phase 2 Single-Arm Study to Evaluate the Efficacy of Isatuximab, Pomalidomide and Low-Dose Dexamethasone, in Patients with AL Amyloidosis Not in VGPR or Better after Any Previous Therapy (IsAMYP)

Murielle Roussel, Peter Mollee, Antoine Huart, Hasib Sidiqi, Noemi Horvath, Lionel Karlin, Caroline Jacquet, Pierre Morel, Cecile Leyronnas, Sebastien Bender, Frank Bridoux, Arnaud Jaccard, Simon D. Gibbs

Blood (2022) 140 (Supplement 1): 12618–12620.

https://doi.org/10.1182/blood-2022-166337

Published: 2022

Journal Articles

Efficacy and Safety of Daratumumab Monotherapy in Newly Diagnosed Patients with Stage 3B Light Chain Amyloidosis: A Phase 2 Study By the European Myeloma Network

Efstathios Kastritis, Monique C. Minnema, Meletios-Athanasios Dimopoulos, Giampaolo Merlini, Foteini Theodorakakou, Despina Fotiou, Antoine Huart, Karim Belhadj, Sreeja Varghese, Kyriaki Manousou, Pieter Sonneveld, Giovanni Palladini

Blood (2022) 140 (Supplement 1): 1841–1843.

https://doi.org/10.1182/blood-2022-168757

Published: 2022

Journal Articles

Efficacy and Safety of Daratumumab Monotherapy in Newly Diagnosed Patients with Stage 3B Light Chain Amyloidosis: A Phase 2 Study By the European Myeloma Network

Efstathios Kastritis, Monique C. Minnema, Meletios A. Dimopoulos, Giampaolo Merlini, Foteini Theodorakakou, Despina Fotiou, Antoine Huart, Karim Belhadj, Alexandros Leonidakis, Kyriaki Manousou, Pieter Sonneveld, Giovanni Palladini

Blood (2021) 138 (Supplement 1): 2730.

https://doi.org/10.1182/blood-2021-152540

Published: 2021

Journal Articles

A prospective phase 2 trial of daratumumab in patients with previously treated systemic light-chain amyloidosis

Blood (2020) 135 (18): 1531–1540.

https://doi.org/10.1182/blood.2019004369

Published: 2020

Includes: Supplemental data

Journal Articles

A Prospective Phase II of Daratumumab in Previously-Treated Systemic Light-Chain (AL) Amyloidosis

Murielle Roussel, MD, Anne-Marie Stoppa, MD, Aurore Perrot, MD, Lionel Karlin, MD, Bertrand Arnulf, MD PhD, Margaret Macro, MD, Antoine Huart, MD, Laurent Frenzel, MD PhD, Pierre Morel, MD, Eileen Boyle, MD, Veronique Dorvaux, MD, Giampaolo Merlini, MD, Giovanni Palladini, MDPhD, David Lavergne, PhD, Frank Bridoux, MD PhD, Arnaud Jaccard

Blood (2017) 130 (Supplement 1): 508.

https://doi.org/10.1182/blood.V130.Suppl_1.508.508

Published: 2017

Journal Articles

Management of noninfectious mixed cryoglobulinemia vasculitis: data from 242 cases included in the CryoVas survey

Blood (2012) 119 (25): 5996–6004.

https://doi.org/10.1182/blood-2011-12-396028

Published: 2012

Includes: Supplemental data

NARROW

Efficacy and Safety of Daratumumab Monotherapy in Newly Diagnosed Patients with Stage 3B Light Chain Amyloidosis: A Phase 2 Study By the European Myeloma Network

Efficacy and Safety of Isatuximab, Pomalidomide and Dexamethasone in Relapsed AL Amyloidosis: Interim Results of the Isamyp Phase 2 Joint Study from the IFM and ALLG

Subcutaneous Daratumumab (DARA) + Bortezomib, Cyclophosphamide, and Dexamethasone (VCd) in Patients with Newly Diagnosed Light Chain (AL) Amyloidosis: Overall Survival and Final Major Organ Deterioration Progression-Free Survival Results from the Phase 3 Andromeda Study

Teclistamab in relapsed or refractory AL amyloidosis: a multinational retrospective case series

Teclistamab in Relapsed Refractory Multiple Myeloma Patients on Dialysis: A French Experience

Efficacy and Safety of Daratumumab Monotherapy in Newly Diagnosed Patients with Stage 3B Light-Chain Amyloidosis: A Phase 2 Study By the European Myeloma Network

Birtamimab: a new amyloidosis treatment?

A Phase 2 Single-Arm Study to Evaluate the Efficacy of Isatuximab, Pomalidomide and Low-Dose Dexamethasone, in Patients with AL Amyloidosis Not in VGPR or Better after Any Previous Therapy (IsAMYP)

Efficacy and Safety of Daratumumab Monotherapy in Newly Diagnosed Patients with Stage 3B Light Chain Amyloidosis: A Phase 2 Study By the European Myeloma Network

Efficacy and Safety of Daratumumab Monotherapy in Newly Diagnosed Patients with Stage 3B Light Chain Amyloidosis: A Phase 2 Study By the European Myeloma Network

A prospective phase 2 trial of daratumumab in patients with previously treated systemic light-chain amyloidosis

A Prospective Phase II of Daratumumab in Previously-Treated Systemic Light-Chain (AL) Amyloidosis

Management of noninfectious mixed cryoglobulinemia vasculitis: data from 242 cases included in the CryoVas survey

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only